Steven Frank Biography and Net Worth

Director of Precigen

Mr. Frank has served as a Board member since February 2008. Mr. Frank joined J.P. Morgan Securities LLC, an investment bank, in June 2008 and currently serves as Chairman of Global Healthcare Investment Banking. Mr. Frank had previously been the head of Bear Stearns’ Worldwide Health Care Investment Banking group in New York for 16 years and has provided general investment banking services to all types of health care companies. Specifically, Mr. Frank has led or played major roles in hundreds of mergers and acquisitions and financing transactions across the spectrum of deal structures. He has specialized in transactions involving pharmaceutical, medical device and biotechnology companies. Prior to joining Bear Stearns in 1993, Mr. Frank served over ten years as an institutional investor, primarily at State Farm Insurance Company, where he focused on a multi-billion dollar life-sciences portfolio. Mr. Frank holds a B.S. from Illinois State University and an M.B.A. from the University of Chicago.

What is Steven Frank's net worth?: The estimated net worth of Steven Frank is at least $3.31 million as of August 14th, 2023. Mr. Frank owns 882,358 shares of Precigen stock worth more than $3,308,843 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Frank may own. Learn More about Steven Frank's net worth.
How do I contact Steven Frank?: The corporate mailing address for Mr. Frank and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Steven Frank's contact information.
Has Steven Frank been buying or selling shares of Precigen?: Steven Frank has not been actively trading shares of Precigen during the last quarter. Most recently, on Monday, August 14th, Steven Frank bought 400,000 shares of Precigen stock. The stock was acquired at an average cost of $1.72 per share, with a total value of $688,000.00. Following the completion of the transaction, the director now directly owns 882,358 shares of the company's stock, valued at $1,517,655.76. Learn More on Steven Frank's trading history.
Who are Precigen's active insiders?: Precigen's insider roster includes Nancy Agee (Director), Steven Frank (Director), Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), Rutul Shah (COO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?: In the last year, Precigen insiders bought shares 6 times. They purchased a total of 54,221 shares worth more than $214,466.77. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 9,950,572 shares worth more than $37,720,436.60. The most recent insider tranaction occured on November, 21st when Director Randal J Kirk sold 937,308 shares worth more than $3,589,889.64. Insiders at Precigen own 47.1% of the company. Learn More about insider trades at Precigen.
Information on this page was last updated on 11/21/2025.

Steven Frank Insider Trading History at Precigen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2023	Buy	400,000	$1.72	$688,000.00	882,358

Steven Frank Buying and Selling Activity at Precigen

Precigen Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Today's Range

Now: $3.75

$3.51

$3.81

50 Day Range

MA: $3.81

$3.12

$4.90

2 Week Range

Now: $3.75

$0.65

$5.22

Volume

1,906,648 shs

Average Volume

4,272,557 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16